Table 3.
Associations between MT2A SNPs and inverted papilloma risk
| SNP genotype | Cases (%)/controls (%) | OR (95 % CI)a | p | OR (95 % CI)b | p |
|---|---|---|---|---|---|
| rs28366003 | |||||
| AA | 98 (75.4)/401 (95.9) | 1.00 (reference) | 1.00 (reference) | ||
| AG | 31 (23.8)/17 (4.1) | 7.46 (3.84–14.47) | <0.001 | 7.43 (3.91–14.46) | <0.001 |
| GG | 1 (0.8)/0 (0.0) | – | |||
| p trendc | <0.0001 | ||||
| AG or GG vs. AAd | 32 (24.6)/17 (4.1) | 7.70 (3.97–14.91) | <0.001 | 7.71 (4.01–14.91) | <0.001 |
| AG or AA vs. GGe | 129 (99.2)/418 (100.0) | – | – | ||
| rs1610216 | |||||
| AA | 96 (73.8)/309 (73.9) | 1.00 (reference) | 1.00 (reference) | ||
| AG | 33 (25.4)/106 (25.3) | 1.00 (0.64–1.58) | 0.99 | 1.01 (0.66–1.58) | 0.99 |
| GG | 1 (0.8)/3 (0.8) | 1.07 (0.11–10.46) | 0.95 | 1.07 (0.10–10.44) | 0.94 |
| p trendc | 0.97 | ||||
| AG or GG vs. AAd | 34 (26.1)/109 (26.1) | 1.00 (0.64–1.57) | 0.99 | 0.99 (0.61–1.56) | 0.99 |
| AG or AA vs. GGe | 129 (99.2)/415 (99.3) | 1.07 (0.11–10.42) | 0.95 | 1.07 (0.13–10.42) | 0.95 |
| rs10636 | |||||
| GG | 58 (44.6)/213 (50.9) | 1.00 (reference) | 1.00 (reference) | ||
| GC | 56 (43.1)/172 (41.2) | 1.19 (0.78–1.82) | 0.40 | 1.23 (0.72–1.82) | 0.40 |
| CC | 16 (12.3)/33 (7.90) | 1.78 (0.91–3.47) | 0.09 | 1.78 (0.94–3.47) | 0.09 |
| p trendc | 0.1 | ||||
| GC or CC vs. GGd | 72 (55.4)/205 (49.0) | 1.29 (0.87–1.92) | 0.21 | 1.30 (0.87–1.95) | 0.22 |
| GC or GG vs. CCe | 114 (87.7)/385 (92.1) | 1.64 (0.87–3.09) | 0.12 | 1.65 (0.83–3.10) | 0.13 |
aCrude
bAdjusted for age, gender, family history and smoking status
cTesting additive genetic model (Cochran-Armitage test for trend)
dTesting dominant genetic model
eTesting recessive genetic model